Repligen (NASDAQ:RGEN) Shares Gap Up - What's Next?

Key Points

• Repligen's share price jumped from a previous close of $149.52 to an opening price of $157.03, with current trading around $154.90 and a trading volume of 184,595 shares.
• Analysts have a positive outlook on Repligen, with multiple firms upgrading the stock to a "buy" or "strong buy" rating, and an average price target of $169.62.
• Insider trading was noted with Director Martin D. Madaus purchasing 1,800 shares at $112.13 each, indicating confidence in the company's future.

Repligen Corporation (NASDAQ:RGEN - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $149.52, but opened at $157.03. Repligen shares last traded at $154.90, with a volume of 184,595 shares changing hands.

Wall Street Analyst Weigh In

Several research firms recently commented on RGEN. Wall Street Zen raised shares of Repligen from a "hold" rating to a "buy" rating in a research note on Saturday, October 11th. Hsbc Global Res upgraded shares of Repligen to a "strong-buy" rating in a report on Wednesday, October 1st. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a report on Tuesday, July 22nd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Finally, HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $169.62.

Repligen Trading Up 2.9%

The company has a 50-day simple moving average of $127.17 and a 200 day simple moving average of $125.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a market capitalization of $8.66 billion, a P/E ratio of -616.70, a P/E/G ratio of 2.74 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares of the company's stock, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by insiders.

Institutional Trading of Repligen

Several hedge funds have recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale lifted its position in shares of Repligen by 1.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company's stock worth $961,000 after purchasing an additional 80 shares during the period. Alliance Wealth Advisors LLC UT grew its holdings in Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 89 shares in the last quarter. Drive Wealth Management LLC raised its position in Repligen by 2.5% in the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company's stock valued at $472,000 after purchasing an additional 93 shares during the last quarter. Hilltop National Bank raised its position in Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company's stock valued at $171,000 after purchasing an additional 95 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Repligen by 4.3% during the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company's stock worth $288,000 after buying an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.